Compounds for treatment of cardiac arrhythmias and heart failure
AssigneeElex Biotech, Inc.
InventorsJosephrajan THAINASHMUTHU, Martha SIBRIAN-VAZQUEZ, Douglas BOATMAN
Life of this patent
Estimating the term…
Abstract
This disclosure concerns compounds and a method for modulating the activity of calcium ion channels, including Ca2+-induced (or Ca2+-activated) calcium release channels and conformationally coupled calcium release channels such as ryanodine receptors. Some of the compounds have a structure according to formula I, or a stereoisomer, tautomer, hydrate, solvate, prodrug, or pharmaceutically acceptable salt thereof.
Claims27
A compound according to formula I, or a stereoisomer, tautomer, pharmaceutically acceptable salt, hydrate, or solvate thereof
- wherein:
- RA is —N(R1)R2 and RB is H, aliphatic, —O-aliphatic, —S-aliphatic, —O—C(O)-aliphatic, or halogen, or RA is N(R1) or —CH2N(R1)— and RA together with RB forms a 5- or 6-membered heteroaliphatic or heteroaryl ring;
- RC is H, aliphatic, —S-aliphatic, or —O—C(O)-aliphatic, and RD is substituted aliphatic or —Y—X—(CR72)m—N(R4)R5, or RC and RD together form a 5- or 6-membered heteroaliphatic or heteroaryl ring, wherein the 5- or 6-membered heteroaliphatic or heteroaryl ring is substituted with —X—(CR72)m—N(R4)R5;
- RE is H, —O-aliphatic, aliphatic, —S-aliphatic, —O—C(O)-aliphatic, or halogen;
- Q is C—R3;
- X is N(R6), O, C(O), —S(O2)O—, —OS(O2)—, —P(O)(OH)O—, —OP(O)OH—, —N(H)—C(H)(CF3)—, or —C(H)(CF3)—N(H)—, or X is absent;
- Y is —(CR72)n— or a divalent azole ring;
- R1 and R2 independently are H or aliphatic;
- R3 is H, aliphatic, —O-aliphatic, or —S-aliphatic;
- R4 and R5 independently are H, aliphatic, aryl or heteroaryl, or R4 and R5 together with N form a heterocycloaliphatic or heteroaryl ring;
- R6 is H or aliphatic;
- each R7 independently is H, halogen, or aliphatic;
- and
- m and n independently are integers from 1 to 10,
- wherein at least one of the following conditions applies
- (i) at least one of RB, RC, RE, and R3 is other than H, or
- (ii) the compound includes —Y—X—(CR72)m—N(R4)R5 or —X—(CR72)m—N(R4)R5, where X is present, or
- (iii) if Y is a divalent azole ring, then X is absent, or
- (iv) if R4 and R5 together with N form a heterocycloaliphatic or heteroaryl ring, then at least of one of RB, RC, RE, and R3 is other than H, or at least one of R1 and R2 is other than H or —CH3;
- or
- (v) if X is absent, then the compound has a structure according to formula III
- where Y is a divalent azole ring;
- or
- (vi) if RC and RD together form a 5- or 6-membered heteroaliphatic or heteroaryl ring, then the compound has a structure according to formula IV or formula VI
- where (a) Z is O, N(H), or CH2, and (b) r is 1 or 2, s is 1 or 2, and r+s=2 or 3, and wherein the compound is not
(canceled)
9-11. (canceled)
13-18. (canceled)
20-22. (canceled)
(canceled)
(canceled)
34-36. (canceled)
Dependencies are inferred from the claim text.